262 related articles for article (PubMed ID: 16819251)
1. Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients.
Shimizu T; Takahashi N; Terakado M; Akusawa H; Tsujino I; Horie T
Intern Med; 2006; 45(11):715-20. PubMed ID: 16819251
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of intrapleural OK-432 and cisplatin for malignant pleural effusion in lung cancer patients].
Shimizu T; Takahashi N; Terakado M; Sato M; Sugane T; Kisohara A; Akusawa H; Tsujino I; Horie T
Gan To Kagaku Ryoho; 2005 Aug; 32(8):1139-43. PubMed ID: 16121916
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.
Hori T; Mise K; Kan N; Okino T; Satoh K; Yamasaki S; Teramura Y; Harada T; Ohgaki K; Kodama H
Biotherapy; 1992; 5(1):21-9. PubMed ID: 1389900
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer.
Kasahara K; Shibata K; Shintani H; Iwasa K; Sone T; Kimura H; Nobata K; Hirose T; Yoshimi Y; Katayama N; Ishiura Y; Kita T; Nishi K; Nakatsumi Y; Ryoma Y; Fujimura M; Nakao S
Anticancer Res; 2006; 26(2B):1495-9. PubMed ID: 16619563
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.
Yoshida K; Sugiura T; Takifuji N; Kawahara M; Matsui K; Kudoh S; Takada M; Fukuoka M; Ariyoshi Y; Fukuda H; Saijo N
Lung Cancer; 2007 Dec; 58(3):362-8. PubMed ID: 17716779
[TBL] [Abstract][Full Text] [Related]
6. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial.
Luh KT; Yang PC; Kuo SH; Chang DB; Yu CJ; Lee LN
Cancer; 1992 Feb; 69(3):674-9. PubMed ID: 1309678
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
Kan N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
[TBL] [Abstract][Full Text] [Related]
8. [Adhesion therapy for malignant pleural effusion (intrapleural administration of OK-432 with minocycline)].
Tanaka A; Sato T
Nihon Kokyuki Gakkai Zasshi; 1999 Jul; 37(7):531-7. PubMed ID: 10481458
[TBL] [Abstract][Full Text] [Related]
9. [Intrathoracic infusion with a combination of low-dose minocycline, OK-432 and cisplatin for malignant pleural effusion].
Ishimori S; Okada S; Yamagata S; Satoh S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):345-9. PubMed ID: 15791817
[TBL] [Abstract][Full Text] [Related]
10. Treating carcinomatous pleural effusion by intrapleural injection of OK-432 in patients with non-small-cell lung cancer.
Chao TY; Hwang WS
Zhonghua Yi Xue Za Zhi (Taipei); 1993 Oct; 52(4):229-34. PubMed ID: 8258114
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of intrapleural or peritoneal repetitive administration of Lentinan and OK-432 for malignant effusion].
Kawaoka T; Yoshino S; Kondo H; Yamamoto K; Hazama S; Oka M
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1565-7. PubMed ID: 16315870
[TBL] [Abstract][Full Text] [Related]
12. OK-432 induces production of neutrophil chemotactic factors in malignant pleural effusion.
Kataoka M; Morishita R; Hiramatsu J; Ueoka H; Nakata Y; Ohnoshi T; Kimura I; Harada M
Intern Med; 1995 May; 34(5):352-6. PubMed ID: 7647401
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer.
Ishida A; Miyazawa T; Miyazu Y; Iwamoto Y; Zaima M; Kanoh K; Sumiyoshi H; Doi M
Respirology; 2006 Jan; 11(1):90-7. PubMed ID: 16423208
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of the combination treatment of intrapleural or intraperitoneal administration of lentinan and OK-432 for malignant effusion].
Yoshino S; Yoshida S; Maeda N; Maeda Y; Maeda K; Hazama S; Oka M
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2798-800. PubMed ID: 21224717
[TBL] [Abstract][Full Text] [Related]
15. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
16. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
Lombardi G; Nicoletto MO; Gusella M; Fiduccia P; Dalla Palma M; Zuin A; Fiore D; Donach M; Zagonel V
Cancer Chemother Pharmacol; 2012 Mar; 69(3):781-7. PubMed ID: 22037881
[TBL] [Abstract][Full Text] [Related]
17. [Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Kikumori T; Hayashi H; Shibata A; Sekiya M; Itoh T; Mase T; Oiwa M; Imai T; Funahashi H
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2091-4. PubMed ID: 10584578
[TBL] [Abstract][Full Text] [Related]
18. Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study.
Choi MG; Park S; Oh DK; Kim HR; Lee GD; Lee JC; Choi CM; Ji W
Thorac Cancer; 2019 Oct; 10(10):1885-1892. PubMed ID: 31389192
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
Li X; Wu G; Chen C; Zhao Y; Zhu S; Song X; Yin J; Lv T; Song Y
Front Immunol; 2021; 12():760683. PubMed ID: 34966384
[TBL] [Abstract][Full Text] [Related]
20. Intrapleural combination therapy with lobaplatin and erythromycin for non-small cell lung cancer-mediated malignant pleural effusion.
Xu L; Wang B; Gao M; Zhang Y; Qi Q; Li T; Li C; Wang A; Li Y
Thorac Cancer; 2018 Aug; 9(8):950-955. PubMed ID: 29917319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
